Radiomics Model Predicts Efficacy of First-Line CDK4/6 Inhibitor Combined with Endocrine Therapy in HR+/HER2− Advanced Breast Cancer

Ying Wei

doi:10.1016/j.acra.2026.07.041

Radiomics Model Predicts Efficacy of First-Line CDK4/6 Inhibitor Combined with Endocrine Therapy in HR+/HER2− Advanced Breast Cancer

2026-08-05

0

PRE

AI

DOI：10.1016/j.acra.2026.07.041

Original

Original request for help

Save

Abstract

En 中文

The combination of CDK4/6 inhibitors and endocrine therapy is the first-line standard regimen for advanced HR⁺/HER₂⁻ breast cancer. However, due to tumor heterogeneity, some patients derive limited benefit. This study aimed to develop and validate a radiomics-based model to predict treatment efficacy.

Radiomics Model Predicts Efficacy of First-Line CDK4/6 Inhibitor Combined with Endocrine Therapy in HR+/HER2− Advanced Breast Cancer

Abstract

Journal

Organization